BioChem, ImmunoGen deal

BCHE and Apoptosis Technology Inc. (Cambridge, Mass.), a 95 percent-owned subsidiary of IMGN, will collaborate to discover and

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE